S a great privilege to be able to take action very positive for those who have choroideremia.
I was sitting on a ship's balcony thinking, 'That is my lot in life just. I'll enjoy the view while I could and keep inside the memory.' And when I came back again, The call was got by me that I qualified for the surgery. The viral vector, referred to as AAV2-REP1, was provided by NightstaRx Ltd., a private British biopharmaceutical company focused on the advancement of therapies for retinal dystrophies. We are leading the way in the advancement of a highly effective gene therapy treatment for choroideremia and this new study, sponsored by the University of Alberta, is another step of progress in the advancement of AAV2-REP1, says David Fellows, CEO of NightstaRx.‘In a letter sent Tuesday to Kathleen Sebelius, secretary of Health and Human Services, Sens. Joseph Lieberman and Susan Collins praised the government’s initial guidelines on the H1N1 swine flu, but stated they now have ‘strong concerns’ about the fallout from faulty estimates for how much vaccine will be available,’ according to the newspaper. ‘Unfortunately, these missteps in estimating obtainable dosages of H1N1 vaccine have effects beyond just growing open public frustration; they have the potential to critically undermine our vaccine distribution efforts, which depend on accurate estimates of vaccine availability,’ the senators wrote. The letter requests that Sebelius ‘answer 13 questions, including when HHS knew that vaccine materials would fall of its projections short, and why officials didn’t narrow their list of target recipients to ensure those at highest risk got the limited materials first’ .